Bulk Manufacturer of Controlled Substances Application: Halo Pharmaceutical, Inc., 48334 [2018-20701]
Download as PDF
<![CDATA[
48334
Federal Register / Vol. 83, No. 185 / Monday, September 24, 2018 / Notices
When respondents complete a fillable
form, they may submit it by uploading
it to a secure webserver, emailing it to
the study team at mtbeffects@usitc.gov,
faxing it, or mailing a hard copy to the
Commission.
III. Request for Comments
they will also become a matter of public
record.
By order of the Commission.
Issued: September 18, 2018.
Lisa Barton,
Secretary to the Commission.
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Halo
Pharmaceutical, Inc.
ACTION:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on July 18,
2018, Halo Pharmaceutical, Inc., 30
North Jefferson Road, Whippany, New
Jersey 07981–1030 applied to be
registered as a bulk manufacturer of the
following basic classes of controlled
substances:
SUPPLEMENTARY INFORMATION:
[FR Doc. 2018–20657 Filed 9–21–18; 8:45 am]
Comments are invited on (1) whether
the proposed collection of information
is necessary; (2) the accuracy of the
agency’s estimate of the burden
(including hours and cost) of the
proposed collection of information; (3)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology.
The draft questionnaire and other
supplementary documents may be
downloaded from the USITC website at
https://www.usitc.gov/MTBEffects.
Comments submitted in response to
this notice will be summarized and/or
included in the request for OMB
approval of this information collection;
Morrissette Drive, Springfield, Virginia
22152.
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before November 23, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
DATES:
Controlled substance
Drug code
Dihydromorphine .............................................................................................................................................................
Hydromorphone ...............................................................................................................................................................
The company plans to manufacture
Hydromorphone (9150) for distribution
to its customers. Dihydromorphine
(9145) as an intermediate in the
manufacture of Hydromorphone and is
not for commercial distribution.
Dated: September 14, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–20701 Filed 9–21–18; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: AMPAC Fine
Chemicals Virginia, LLC
amozie on DSK3GDR082PROD with NOTICES1
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF JUSTICE
ACTION:
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before November 23, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
Notice of application.
Drug code
Phenylacetone .................................................................................................................................................................
Morphine ..........................................................................................................................................................................
Thebaine ..........................................................................................................................................................................
Noroxymorphone .............................................................................................................................................................
17:40 Sep 21, 2018
Jkt 244001
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
I
II
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on April
19, 2018, AMPAC Fine Chemicals
Virginia, LLC, 2820 North Normandy
Drive, Petersburg, Virginia 23805–2380
applied to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Controlled substance
VerDate Sep<11>2014
9145
9150
Schedule
E:\FR\FM\24SEN1.SGM
24SEN1
8501
9300
9333
9668
Schedule
II
II
II
II
]]>Agencies
[Federal Register Volume 83, Number 185 (Monday, September 24, 2018)]
[Notices]
[Page 48334]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-20701]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Halo
Pharmaceutical, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before November 23, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on July
18, 2018, Halo Pharmaceutical, Inc., 30 North Jefferson Road, Whippany,
New Jersey 07981-1030 applied to be registered as a bulk manufacturer
of the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Dihydromorphine.................... 9145 I
Hydromorphone...................... 9150 II
------------------------------------------------------------------------
The company plans to manufacture Hydromorphone (9150) for
distribution to its customers. Dihydromorphine (9145) as an
intermediate in the manufacture of Hydromorphone and is not for
commercial distribution.
Dated: September 14, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-20701 Filed 9-21-18; 8:45 am]
BILLING CODE 4410-09-P
